Cargando…
Catecholamines in Alzheimer's Disease: A Systematic Review and Meta-Analysis
Background and Purpose: Previous studies found inconsistent results regarding the relationship between Alzheimer's disease (AD) and catecholamines, such as dopamine (DA), norepinephrine (NE), and epinephrine (EPI). Therefore, the purpose of this study was to perform a systematic review and meta...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7516036/ https://www.ncbi.nlm.nih.gov/pubmed/33024430 http://dx.doi.org/10.3389/fnagi.2020.00184 |
_version_ | 1783586924625133568 |
---|---|
author | Pan, Xiongfeng Kaminga, Atipatsa C. Jia, Peng Wen, Shi Wu Acheampong, Kwabena Liu, Aizhong |
author_facet | Pan, Xiongfeng Kaminga, Atipatsa C. Jia, Peng Wen, Shi Wu Acheampong, Kwabena Liu, Aizhong |
author_sort | Pan, Xiongfeng |
collection | PubMed |
description | Background and Purpose: Previous studies found inconsistent results regarding the relationship between Alzheimer's disease (AD) and catecholamines, such as dopamine (DA), norepinephrine (NE), and epinephrine (EPI). Therefore, the purpose of this study was to perform a systematic review and meta-analysis to evaluate the results of previous studies on this relationship. Method: Literature retrieval of eligible studies was performed in four databases (Web of Science, PubMed, Embase, and PsycARTICLES). Standardized mean differences (SMDs) were calculated to assess differences in catecholamine concentrations between the AD groups and controls. Results: Thirteen studies met the eligibility criteria. Compared with the controls, significant lower concentrations of NE (SMD = −1.10, 95% CI: −2.01 to −0.18, p = 0.019) and DA (SMD = −1.12, 95% CI: −1.88 to −0.37, p = 0.003) were observed in patients with AD. No difference was found in the concentrations of EPI between the two groups (SMD = −0.74, 95% CI: −1.85 to 0.37, p = 0.189). Conclusion: Overall, these findings are in line with the hypothesis that reduced NE and DA may be an important indicator for AD (Registration number CRD42018112816). |
format | Online Article Text |
id | pubmed-7516036 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-75160362020-10-05 Catecholamines in Alzheimer's Disease: A Systematic Review and Meta-Analysis Pan, Xiongfeng Kaminga, Atipatsa C. Jia, Peng Wen, Shi Wu Acheampong, Kwabena Liu, Aizhong Front Aging Neurosci Neuroscience Background and Purpose: Previous studies found inconsistent results regarding the relationship between Alzheimer's disease (AD) and catecholamines, such as dopamine (DA), norepinephrine (NE), and epinephrine (EPI). Therefore, the purpose of this study was to perform a systematic review and meta-analysis to evaluate the results of previous studies on this relationship. Method: Literature retrieval of eligible studies was performed in four databases (Web of Science, PubMed, Embase, and PsycARTICLES). Standardized mean differences (SMDs) were calculated to assess differences in catecholamine concentrations between the AD groups and controls. Results: Thirteen studies met the eligibility criteria. Compared with the controls, significant lower concentrations of NE (SMD = −1.10, 95% CI: −2.01 to −0.18, p = 0.019) and DA (SMD = −1.12, 95% CI: −1.88 to −0.37, p = 0.003) were observed in patients with AD. No difference was found in the concentrations of EPI between the two groups (SMD = −0.74, 95% CI: −1.85 to 0.37, p = 0.189). Conclusion: Overall, these findings are in line with the hypothesis that reduced NE and DA may be an important indicator for AD (Registration number CRD42018112816). Frontiers Media S.A. 2020-09-11 /pmc/articles/PMC7516036/ /pubmed/33024430 http://dx.doi.org/10.3389/fnagi.2020.00184 Text en Copyright © 2020 Pan, Kaminga, Jia, Wen, Acheampong and Liu. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Neuroscience Pan, Xiongfeng Kaminga, Atipatsa C. Jia, Peng Wen, Shi Wu Acheampong, Kwabena Liu, Aizhong Catecholamines in Alzheimer's Disease: A Systematic Review and Meta-Analysis |
title | Catecholamines in Alzheimer's Disease: A Systematic Review and Meta-Analysis |
title_full | Catecholamines in Alzheimer's Disease: A Systematic Review and Meta-Analysis |
title_fullStr | Catecholamines in Alzheimer's Disease: A Systematic Review and Meta-Analysis |
title_full_unstemmed | Catecholamines in Alzheimer's Disease: A Systematic Review and Meta-Analysis |
title_short | Catecholamines in Alzheimer's Disease: A Systematic Review and Meta-Analysis |
title_sort | catecholamines in alzheimer's disease: a systematic review and meta-analysis |
topic | Neuroscience |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7516036/ https://www.ncbi.nlm.nih.gov/pubmed/33024430 http://dx.doi.org/10.3389/fnagi.2020.00184 |
work_keys_str_mv | AT panxiongfeng catecholaminesinalzheimersdiseaseasystematicreviewandmetaanalysis AT kamingaatipatsac catecholaminesinalzheimersdiseaseasystematicreviewandmetaanalysis AT jiapeng catecholaminesinalzheimersdiseaseasystematicreviewandmetaanalysis AT wenshiwu catecholaminesinalzheimersdiseaseasystematicreviewandmetaanalysis AT acheampongkwabena catecholaminesinalzheimersdiseaseasystematicreviewandmetaanalysis AT liuaizhong catecholaminesinalzheimersdiseaseasystematicreviewandmetaanalysis |